

Message

From: Schnee,Dr.,Janet (CR) BIP-US-R [/O=BOEHRINGER-INGELHEIM/OU=RIDGEFIELD/CN=RECIPIENTS/CN=JSCHNEE]
Sent: 12/19/2011 10:21:40 PM
To: Clemens,Dr.,Andreas (ClinD&MedA) BIP-DE-I [andreas.clemens@boehringer-ingelheim.com]
Subject: RE: RELY PK exposure-response paper

Dear Andreas,

I noticed this email only this evening, but have now forwarded it to the US product lawyer for an opinion. She and I are currently both out on PTO until the first week of January, but I am hopeful that I will be able to discuss the posed question before then.

Best regards,
Janet

From: Clemens,Dr.,Andreas (ClinD&MedA) BIP-DE-I
Sent: Monday, December 19, 2011 12:42 PM
To: Schnee,Dr.,Janet (CR) BIP-US-R
Cc: Friedman,Dr.,Jeffrey (CR) BIP-US-R; Reilly,Dr.,Paul (CR) BIP-US-R; Brueckmann,Prof.Dr.,Martina (ClinD&MedA) BIP-DE-I
Subject: WG: RELY PK exposure-response paper
Importance: High

Dear Janet,

I was asked by Jeff to forward the attached draft paper about PK exposure – response to you for your review and information. Explicitly we need to clarify because of mentioning of an optimal range of dabigatran treated patients if there could be a liability issue when BI authors are on this manuscript.

Maybe I am phobic, but I am not happy with the conclusion: An optimal balance between benefit and risk occurs in the range of concentrations between 40 and 215 ng/mL

Additionally I am not sure how physicians in US should evaluate the dabigatran plasma levels in practice as hemoclot is not available. Beside the conclusion above from my point of view the manuscript goes beyond what can be said regarding recommendations.

Please could you check with the appropriate legal guys if there is the possibility of issues for BI when this will be published.

Mit freundlichen Grüßen / Kind regards,

Andreas Clemens

Dr. Andreas Clemens

Boehringer Ingelheim Pharma GmbH & Co. KG
TA Cardiology
Tel.: +49 (0)132 77-90606
Fax: +49 (0)132 72-90606
mailto:andreas.clemens@boehringer-ingelheim.com

Boehringer Ingelheim Pharma GmbH & Co. KG, Sitz: Ingelheim am Rhein; Registergericht Mainz: HR A 22206; Komplementär
Boehringer Ingelheim Deutschland GmbH; Geschäftsführung: Dr. Engelbert Günster (Vorsitzender), Ralf Gorniak, Mark
Hegmann, Michael Klein, Dr. Martin Wanning; Vorsitzender des Aufsichtsrates: Prof. Dr. Dr. Andreas Barner; Sitz: Ingelheim am
Rhein; Registergericht Mainz: HR B 23260

Confidential Information – Subject to Confidentiality Order

BIPI-PRA-0004588740



597854

Diese E-Mail ist vertraulich zu behandeln. Sie kann besonderem rechtlichen Schutz unterliegen. Wenn Sie nicht der richtige Adressat sind, senden Sie bitte diese E-Mail an den Absender zurück, löschen die eingegangene E-Mail und geben den Inhalt der E-Mail nicht weiter. Jegliche unbefugte Bearbeitung, Nutzung, Vervielfältigung oder Verbreitung ist verboten. / This e-mail is confidential and may also be legally privileged. If you are not the intended recipient please reply to sender, delete the e-mail and do not disclose its contents to any person. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited.

Von: Brueckmann, Prof. Dr., Martina (ClinD&MedA) BIP-DE-I
Gesendet: Sonntag, 18. Dezember 2011 23:06
An: Clemens, Dr., Andreas (ClinD&MedA) BIP-DE-I
Betreff: RELY PK exposure-response paper

Hallo Andreas,

find attached the revised exposure-response paper by Paul, which I received yesterday via the RELY Operations committee for review. It will be discussed in the call on Monday afternoon.

I am not aware whether you or Jeff have already seen this paper. The paper suggests something like a therapeutic range for dabigatran based on risk of bleeding an stroke between the 10-90th percentile of plasma concentrations. I am not sure if we are fully committed to go this route especially as we are lacking an assay to measure dabigatran in the US. Please have a look and let me know what you think.

Find attached a version with my comments in it.

Kind regards,
Martina

<< File: Concentration response ver 5 Dec 14 2011_MB.docx >>

Dr. Martina Brückmann
Boehringer Ingelheim GmbH & Co KG
Clinical Development and Medical Affairs
TA Cardiology
Binger Straße 173
55216 Ingelheim am Rhein
Germany

Tel.: +49 (6132) 77-7641
Fax: +49 (6132) 72-7641
mailto:martina.brueckmann@boehringer-ingelheim.com